Table II.
Copeptin in prediction of combined end point and its components in individuals with or without diabetes
Diabetic cases |
Nondiabetic cases |
||||||||
---|---|---|---|---|---|---|---|---|---|
n total/n event | HR (95% CI) | P⁎ | P† | P‡ | P§ | n total/n event | HR (95% CI) | P⁎ | |
Primary end point (CAD + death + HF)║ | 895/287 | 1.32 (1.10-1.58) | .003 | .02 | .02 | .002 | 4187/845 | 1.01 (0.95-1.09) | .70 |
CAD ¶ | 895/164 | 1.33 (1.04-1.69) | .02 | .048 | .053 | .03 | 4187/319 | 1.02 (0.90-1.15) | .78 |
HF# | 895/58 | 1.62 (1.09-2.41) | .02 | .04 | .04 | .02 | 4187/95 | 1.22 (0.94-1.58) | .13 |
Death ║ | 895/165 | 1.32 (1.04-1.68) | .02 | .13 | .17 | .01 | 4187/599 | 1.00 (0.92-1.08) | .92 |
HRs are expressed as per SD increment of ln-transformed copeptin.
Adjusted for age, sex, LDL, HDL, systolic blood pressure, antihypertensive treatment, and smoking (model 1).
Model adjusted for glucose on top of model 1 adjustment.
Model adjusted for HbA1c on top of model 1 adjustment.
Model adjusted for Insulin on top of model 1 adjustment.
Model adjusted for prevalent CAD and prevalent HF on top of model 1 adjustment.
Model adjusted for prevalent CAD on top of model 1 adjustment.
Model adjusted for prevalent HF on top of model 1 adjustment.